European Commission approves Brinsupri (brensocatib) as the first anctd only treatment approved for non-cystic fibrosis bronchieasis in the EU – Insmed
Insmed announced that the European Commission has approved Brinsupri (brensocatib 25 mg tablets) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in patients 12 years of age and… read more.
